Lymphoma Clinical Trials in Arizona

Showing 121-140 of 252 trials

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

NCT04186637

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without available standard or curative therapy.

Advanced Solid TumorLymphoma

Alpine Immune Sciences, Inc.62 participantsStarted Jun 2020

Scottsdale, Arizona, United States • New Haven, Connecticut, United States • Lafayette, Indiana, United States +7 more locations

TERMINATEDPHASE131 miles

Safety Study of SEA-CD40 in Cancer Patients

NCT02376699

This study is being done to find out if SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel. The study will test increasing doses of SEA-CD40 given at least every 3 weeks to small groups of patients. The goal is to find the highest dose of SEA-CD40 that can be given to patients that does not cause unacceptable side effects. Different dose regimens will be evaluated. Different methods of administration may be evaluated. The pharmacokinetics, pharmacodynamic effects, biomarkers of response, and antitumor activity of SEA-CD40 will also be evaluated.

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellHodgkin Disease+17 more

Seagen Inc.159 participantsStarted Feb 2015

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +16 more locations

PreviousPage 7 of 13Next

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Safety Study of SEA-CD40 in Cancer Patients

Lymphoma Trials in Other Cities

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)

Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

Other Conditions in Arizona